CD40LG and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib treatment in children with chronic phase CML (CML-CP) prompts low-for-age immunoglobulin levels and IgG, IgA, and IgM levels are reduced in 30%, 27%, and 33% of patients, respectively (17% with pan-HGG), while HGG is associated neither with the duration nor with the dose of imatinib treatment [107].